Indication assessment · §3
Immune modulation and adjunctive immunotherapy — trial records
Trial records in the Institute's register bearing on immune modulation and adjunctive immunotherapy.
§3Trials in this indication
24 trial records in the Institute's register bear on this indication, of which 5 are published trials.
Table 2. Trial records bearing on immune modulation and adjunctive immunotherapy.
| Record | Compound | Phase | Design | Randomised | Year |
|---|---|---|---|---|---|
| TA1-HBV-1 | Thymosin alpha-1 | Phase 3 | Randomised, double-blind, active-controlled | — | 2001 |
| TA1-HCV-1 | Thymosin alpha-1 | Phase 3 | Randomised, double-blind, active-controlled | — | 2004 |
| TA1-SEPSIS-CN | Thymosin alpha-1 | Phase 3 | Randomised, double-blind, placebo-controlled | 361 | 2013 |
| TA1-VACCINE-ELDERLY | Thymosin alpha-1 | Phase 2 | Randomised, double-blind, placebo-controlled | — | 1998 |
| THYMALIN-RU-1 | Thymalin | — | Observational | — | — |
| TA1-HBV-1-REGIONAL-JPprogramme record | Thymosin alpha-1 | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2001 |
| TA1-HCV-1-REGIONAL-CNprogramme record | Thymosin alpha-1 | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2004 |
| TA1-SEPSIS-CN-ADHERENCEprogramme record | Thymosin alpha-1 | Phase 3 | Observational | — | 2013 |
| TA1-VACCINE-ELDERLY-BODY-COMPprogramme record | Thymosin alpha-1 | Phase 2 | Randomised, double-blind, placebo-controlled | — | 1998 |
| THYMALIN-RU-1-ELDERLYprogramme record | Thymalin | — | Randomised, double-blind, placebo-controlled | — | — |
| TA1-HBV-1-BODY-COMPprogramme record | Thymosin alpha-1 | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2001 |
| TA1-HCV-1-QOLprogramme record | Thymosin alpha-1 | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2004 |
| TA1-SEPSIS-CN-BIOMARKERprogramme record | Thymosin alpha-1 | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2013 |
| TA1-VACCINE-ELDERLY-REGIONAL-JPprogramme record | Thymosin alpha-1 | Phase 3 | Randomised, double-blind, placebo-controlled | — | 1998 |
| THYMALIN-RU-1-OLEprogramme record | Thymalin | — | Single-arm open-label | — | — |
| TA1-HBV-1-QOLprogramme record | Thymosin alpha-1 | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2001 |
| TA1-HCV-1-BODY-COMPprogramme record | Thymosin alpha-1 | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2004 |
| TA1-SEPSIS-CN-ELDERLYprogramme record | Thymosin alpha-1 | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2013 |
| TA1-VACCINE-ELDERLY-REGIONAL-CNprogramme record | Thymosin alpha-1 | Phase 3 | Randomised, double-blind, placebo-controlled | — | 1998 |
| THYMALIN-RU-1-ADHERENCEprogramme record | Thymalin | — | Observational | — | — |
| TA1-HBV-1-REGIONAL-CNprogramme record | Thymosin alpha-1 | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2001 |
| TA1-HCV-1-REGIONAL-JPprogramme record | Thymosin alpha-1 | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2004 |
| TA1-SEPSIS-CN-OLEprogramme record | Thymosin alpha-1 | Phase 3 | Single-arm open-label | — | 2013 |
| TA1-VACCINE-ELDERLY-QOLprogramme record | Thymosin alpha-1 | Phase 2 | Randomised, double-blind, placebo-controlled | — | 1998 |
| This facet in the trial register. | |||||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Garaci E, Pica F, Serafino A, Balestrieri E, Matteucci C, Moroni G, Sorrentino R, Zonfrillo M, Pierimarchi P, Sinibaldi-Vallebona P. Thymosin α1 and cancer: action on immune effector and tumor target cells. Annals of the New York Academy of Sciences 2007;1112:225–234. doi:10.1196/annals.1415.025 · PMID 17567944
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-IN-28/3 · https://compoundevidence.com/indications/immune-support/trials/ · retrieved 30 July 2026